Navigation Links
Myelin Associated With Early Evolution of Huntington's Disease

A new study has found that a breakdown of myelin is associated with the early evolution of Huntington's disease. Last month, Dr. George Bartzokis, director of the UCLA Memory Disorders and Alzheimer's Disease Clinic, suggested in the journal Alzheimer's and Dementia that the collapse of a type of myelin that develops late in life promotes the enlargement of toxic amyloid plaques long associated with Alzheimer's disease. Myelin is the "insulation" that wraps around nerve axons in the brain.

Now, in a new report presently online in the journal Neurochemical Research, Bartzokis turns his concentration to Huntington's disease. Again, he suggests that a breakdown of myelin is the cause, but with a twist - it is the myelin that develops early in the formation of the brain that breaks down ahead of time and ultimately leads to the disease's symptoms.

Huntington's disease (HD) is an uncommon, inherited neurological disorder that eventually deprives individuals of their ability to be in charge of their movement, behaviour and thinking. It affects around 30,000 people in the U.S., with another 150,000 at risk.

While it is known that HD is caused by a mutation in a gene called Huntingtin (Htt), the correct mechanism by which the Htt gene causes or contributes to neuronal cell death and HD symptoms remains uncertain. Bartzokis' research suggests that it is Htt's influence on myelin that may prove to be the cause.

The earliest parts of the developing brain include systems of neurons that control movement and behaviour. These neurons have long axons, finger-like projections that serve as the main transmission lines of the nervous system, covered with thick myelin sheaths. The sheaths are nourished by an ongoing supply of a protein called brain-derived neurotrophic factor, which travels down a neuron's axon.

Bartzokis believes that the Htt gene gets in the way of this nourishment-delivery system, causing a breakdown of the myelin that depends on it. That, consecutively, upsets cell signalling, which results in the neuron's death.

The problem is compounded by the recurrent production of other cells that carry on making myelin. In HD, increasing numbers of these cells, called oligodendrocytes, are created in an effort to remyelinate axons whose myelin sheaths have broken down. This results in markedly elevated numbers of oligodendrocytes years before the appearance of HD symptoms.

Such elevation is damaging because oligodendrocytes are rich with iron, which, while required for myelination, is also a recognized catalyst of free-radical-induced tissue damage. Iron accumulates during normal aging, and abnormal iron metabolism is believed to be involved in many human disorders.

To spot myelin destruction, neuron death and iron accumulation in the brains of HD subjects, Bartzokis used two magnetic resonance imaging (MRI) machines operating at different field strengths. Measurements of myelin breakdown and iron content were taken from the brains of 11 HD subjects and compared to a control group of 27 subjects. Bartzokis found that both the breakdown and the iron accumulation matched the typical progression of the disease from early to late myelinating regions.

Thus, according to Bartzokis, earlier myelinated axons, such as the ones controlling movement, take the strain of damage from the mutant gene in the disease. "And the early symptoms of Huntington's are problems with controlling movement, behavior and eventually thinking," Bartzokis said.

The implications of this are significant, Bartzokis noted, since there is a decades-long period during which therapeutic interventions could alter the course of the disease, long before clinical evidence - such as behavioral, cognitive and motor problems - appear. Thus, it may be achievable to build up medication that could be controlled in the very early stages using no n-invasive in vivo neuroimaging markers of both myelin breakdown and levels of iron.


'"/>




Related medicine news :

1. Blame Myelin for Many Neuropsychiatric Disorders
2. Moderate Use of Analgesics - Not Associated With Kidney Dysfunction
3. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
4. Associated therapy for multiple myeloma
5. Associated scan for detecting ovarian cancer spread
6. Ginseng Associated with Pregnancy Risks
7. Enzyme Associated with Memory
8. 3 die, 500 sickened in nations largest hepatitis A outbreak Associated Press
9. Enzyme Associated With Memory
10. Problems Associated With Iron Deficiency
11. Asbestos Exposure Associated With An Increased Risk For Autoimmune Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only nursing ... upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA on October 23, ... Virginia Mason Health System in Seattle since 2000. In addition to his role at ...
(Date:2/23/2017)... ... 23, 2017 , ... HealthPostures, the desk for standing designer headquartered in Prior ... to the Minneapolis Home and Garden Show which is being held February 24 through ... attention is the Minneapolis Convention Center. , From its broad line of sit ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it ... healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s ... systems recently invested $51 million to purchase and renovate the 185,000 square-foot office ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem ... recent years. The technology is so cutting edge, in fact, the U.S. Food ... stem cell procedures. However, successful patient outcomes in certain clinical stem cell procedures ...
(Date:2/22/2017)... ... 2017 , ... The National Academy of Certified Care Managers ... 2017 testing period. NACCM, a nonprofit organization, has provided the premier certification for ... periodically re-calibrated to ensure that newly certified professionals are prepared to work effectively ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology: